Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Palbociclib plus an aromatase inhibitor|DRUG: Palbociclib plus fulvestrant
Sponsor: Pfizer